Main > NEUROLOGY. > Multiple Sclerosis > Genetics > Retro Virus 1 & 2. > Nucleotide Sequence.

Product France. B

PATENT ASSIGNEE'S COUNTRY France
UPDATE 12.99
PATENT NUMBER This data is not available for free
PATENT GRANT DATE 14.12.99
PATENT TITLE Isolated nucleotide sequences associated with Multiple sclerosis

PATENT ABSTRACT Viral material, in the isolated or purified state, in which the genome comprises a nucleotide sequence chosen from the group including sequences SEQ ID NO:46, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53 and SEQ ID NO:56, their complementary sequences and their equivalent sequences, in particular nucleotide sequences displaying, for any succession of 100 contiguous monomers, at least 50% and preferably at least 70% homology with the said sequences SEQ ID NO:46, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53 and SEQ ID NO:56, respectively, and their complementary sequences.

PATENT INVENTORS This data is not available for free
PATENT ASSIGNEE This data is not available for free
PATENT FILE DATE 02.08.96
PATENT FOREIGN APPLICATION PRIORITY DATA This data is not available for free
PATENT REFERENCES CITED Acha-Orbea et al., "M1s--A Retrovirus Exploits the Immune System", Immunology Today, vol. 12, No. 10, 1991, pp. 356-361.
Asai et al., "J. of Neurochem", vol. 59, No. 1, pp. 307-317, 1992.
ATCC Catalogue of Cell Lines and Hybridomas, Sixth Edition, 1988, pp. 165 and 344-355.
C.R.M. Bangham et al., "PCR Anlaysis of DNA from Multiple Sclerosis Patients for the Presence of HTLV-I", Science, vol. 246, Nov. 10, 1989, pp. 821-824.
R. Baccala et al., "Genomically Imposed and Somatically Modified Human Thymocyte vb Gene Repertoires", Proc. Natl. Acad. Sci., vol. 88, pp. 2908, 1991.
J. Bai et al., "Unique Long Terminal repeat U3 Sequences Distinguish Exogenous Jaagsiekte Sheep Retroviruses Associated with Ovine Pulmonary Carcinoma from Endogenous Loci in the Sheep Genome", J. Virol., vol. 70, pp. 3159-3168, (1996).
Barna et al., "Human Astrocytes Proliferate in Response to Tumor Necrosis Factor Alpha", J. Neuroimmunol., 30 (1990), pp. 239-243.
Beck et al., "Increased Production of Interferon Gamma and Tumor Necrosis Factor Precedes Clinical Manifestation in Multiple Sclerosis: Do Cytokines Trigger Off Exacerbations?", Acta Neurol. Scand., 1988: 78, pp. 318-323.
J. I. Bell et al., "Multiple Loci for Multiple Sclerosis", Nature Genetics, vol. 13, pp. 377-378, (1996).
Bergamini et al., "Multiple Sclerosis. I. The Immune Pathogenetic Hypothesis", Riv. Neurol., vol. 59, No. 5, Oct. 1989, pp. 176-190.
T. Bergstrom et al., "Isolation of Herpes Virus Type 1 During First Attack of Multiple Sclerosis.", Annales Neurology, vol. 26, pp. 283-285, (1989).
Bernton et al., "No Direct Neuronotoxicity by HIV-1 Virions or Culture Fluids from HIV-1 Infected T Cells or Monocytes", Aids Research and Human Retroviruses, vol. 8, No. 4, 1992, pp. 495-503.
Birnbaum et al., "Spinal Fluid Lymphocytes from a SubGroup of Multiple Sclerosis Patients Respond to Mycobacterial Antigens", Ann. Neurol., vol. 34, No. 1, Jul. 1993, pp. 18-24.
Bjare, "Serum-Free Cell Culture", Pharmac. Ther., vol. 53, 1992, pp. 355-374.
C. Bosgiraud et al., "Ultrastructural Study on Visna Virus in Sheep Plexus Choroid Cells", Biological Abstracts, vol. 83, No. 7, 1987.
D. Ross Boswell et al., "Sequence comparison and alignment: the measurement and interpretation of sequence similarity", Computational Molecular Biology, Sources and Methods for Sequence Analysis, pp. 161-178.
Boyle et al., "Cellular Immune Response in Multiple Sclerosis Plaques", American Journal of Pathology, vol. 137, No. 3, Sep. 1990, pp. 575-584.
Bradford, A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding, Anal. Biochem., 72, 1976, pp. 248-254.
Brocke et al., "Induction of Relapsing Paralysis in Experimental Autoimmune Encephalomyelitis by Bacterial Superantigen", Nature, vol. 365, Oct. 14, 1993, pp. 642-644.
Calder, et al., "MS: A Localized Immune Disease of the Central Nervous System", Immunology Today, vol. 10, No. 3, 1989, pp. 99-103.
Carp et al., "Viral Etiology of Multiple Sclerosis", Prog. Med. Virol., vol. 24, pp. 158-177, 1978.
Charcot, "Histologie de la sclerose en plaques [Histology of Multiple Sclerosis]", Gaz. Hop. (Paris), 1868; 41, 554-566.
Chomczynski et al., "Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate-Phenol-Chloroform Extraction", Anal. Biochem., 1987, vol. 162, pp. 156-159.
Cole et al., "The Mycoplasma Arthritidis T-Cell Mitogen, MAM: A Model Superantigen", Immunology Today, vol. 12, No. 8, 1991, pp. 271-276.
Cook et al., "Multiple Sclerosis and Distemper in Iceland 1966-1978", Acta Neurol. Scandinav. 61, 1980, pp. 244-251.
Dalgleish et al., "Do Human T-Lymphotrophic Viruses (HTLVs) and Other Enveloped Viruses Induce Autoimmunity in Multiple Sclerosis?", Neuropath. App. Neurobiol., 1987, 13, pp. 241-250.
A. N. Davison et al., "Biosynthesis of Myelin and Neurotoxic Factors in the Serum of Multiple Sclerosis Patients", Advances in Experimental Medicine and Biology, vol. 100, pp. 19-25, 1978.
De Keyser, "Autoimmunity in Multiple Sclerosis", Neurology, 38, Mar. 1988, pp. 371-374.
S. Dhib-Jalbut et al., "Measles Virus Polypeptide-Specific Antibody Profile in Multiple Sclerosis", Neurology, vol. 40, pp. 430-435, (1990).
Dunn et al., "A Novel Method to Map Transcripts: Evidence for Homology Between an Adenovirus mRNA and Discrete Multiple Regions of the Viral Genome", Cell, vol. 12, Sep. 1977, pp. 23-36.
Ebers et al., "The Geography of MS Reflects Genetic Susceptibility", Neurology, 36, Apr. 1986, Suppl. 1, p. 108.
Elian et al., "Multiple Sclerosis Among United Kingdom-Born Children of Immigrants from the Indian Subcontinent, Africa and the West Indies", J Neurol Neurosurg Psychiat, 1990; 53, pp. 906-911.
Escourolle et al., "Principales Donnees Morphologiques Approches Physiopathologiques et Etiologiques de la Sclerose en Plaques [Principal Morphological Data, Physiopathological and Etiological Approaches to Multiple Sclerosis]", La Reveue du Praticien, Paris, 1980; 30, pp. 2047-2053.
E. J. Field, "Immunological Treatment for Multiple Sclerosis", The Lancet, Jun. 3, 1989, p. 1272.
Frohman et al., "Rapid Production of Full-Length cDNAs from Rare Transcripts: Amplification Using a Single Gene-Specific Oligonucleotide Primer", Proc. Natl. Acad. Sci. USA, 1988, vol. 85, pp. 8998-9002.
Medline Abstract of FU et al., "Rabies virus nucleoprotein expressed in and purified from insect cells is efficacious as a vaccine," Proc Natl Acad Sci USA 88: 2001-2005 (1991).
Galiana et al., "Establishment of Permanent Astroglial Cell Lines, Able to Differentiate in Vitro, From Transgenic Mice Carrying the Polyoma Virus Large T Gene: An Alternative Approach to Brain Cell Immortalization", Journal of Neuroscience Research, 1990; 26: 269-277.
M. B. Gardner et al., "Congenital Transmission of Murine Leukaemia Virus from Wild Mice Prone to Development of Lymphoma and Paralysis", J. Natl. Cancer Inst., vol. 62, pp. 63-69, (1979).
M. B. Gardner, Genetic resistance to a Retroviral Neurologic Disease in Wild Mice, in "Retrovirus Infections of the Nervous System", Oldstone M.B.A. and Koprowsky H. Eds. Current Topice in Microbiology and Immunology, No. 160, pp. 3-10, (Springer-Verlag, Berlin, 1990).
Gay, "Is Multiple Sclerosis Caused by an Oral Spirochaete", The Lancet, Jul. 12, 1986, pp. 75-77.
A. Gessain et al., "Intrathecal Systhesis of Antibodies to Human T Lymphotropic Virus Type I and the Presence of IgG Oligoclonal Bands in the Cerebrospinal Fluid of Patients with Endemic Tropical Spastic Paraparesis", The Journal of Infectious Diseases, vol. 157, No. 6, Jun. 1988, pp. 1226-1234.
A. Gessain et al., Antibodies to Human T-Lymphotrophic Virus type-I in Patients with Tropical Spastic Paraparesis, Lancet, vol. 2, pp. 407-410, (1985).
Giulian et al., "The Envelope Glycoprotein of Human Immunodeficiency Virus Type 1 Stimulates Release of Neurotoxins from Monocytes", Proc. Natl. Acad. Sci. USA, vol. 90, 1993, pp. 2769-2773.
D. Giulian et al., "Secretion of Neurotoxins by Mononuclear Phagocytes Infected with HIV-1", Science, vol. 250, Dec. 14, 1990, pp. 1593-1596.
Gonzalez-Scarano et al., "Multiple Sclerosis Disease Activity Correlates with Gadolinium-Enhanced Magnetic Resonance Imaging", Annals of Neurology, vol. 21, No. 3, Mar. 1987, pp. 300-306.
F. Gonzalez-Scarano et al., "Sequence Similarities Between Human Immunodeficiency Virus gp41 and Paramyxovirus Fusion Proteins.", AIDS Res. Hum. Retrov., vol. 3, pp. 245-252, (1987).
R. Gonzales-Quintial et al., J. Clin. Invest., vol. 97, No. 5, pp. 1335-1343, 1996.
S.J. Greenberg et al., "Detection of sequences homologous to human retroviral DNA in multiple sclerosis by gene amplification", Proc. Natl. Acad. Sci. USA, vol. 86, Apr. 1989, pp. 2878-2882.
S. Haahr et al., "A Putative New Retrovirus Associated with Multiple Sclerosis and the Possible Involvement of Epstein-Barr Virus in this Disease", NY Acad. Science, vol. 724, pp. 148-156, 1994.
S. Haahr et al., "Is Multiple Sclerosis Caused by a Dual Infection with Retrovirus and Epstein-Barr Virus?", Neuroepidemiology, vol. 11, pp. 299-303, (1992).
S. Haahr et al., "Just Another Dubious Virus in Cells from a Patient with Multiple Sclerosis?", The Lancet, vol. 337, Apr. 6, 1991, pp. 863-864.
A. T. Haase, "Pathogenesis of Lentivirus Infections", Nature, vol. 322, Jul. 10, 1986, pp. 130-136.
Haegert et al. HLA-Dr.beta., -DQ.alpha., and -DQ.beta. Restriction Fragment Length Polymorphisms in Multiple Sclerosis, J. Neurosci. Res., 1989; 23, pp. 46-54.
S.L. Hauser et al., "Analysis of Human T-lymphotropic virus sequences in multiple sclerosis tissue", Nature, vol. 322, Jul. 10, 1986, pp. 176-178.
Hauw et al., "Aspects Anatomo-Pathologiques de la Sclerose en Plaques [Anatomopathological Aspects of Multiple Sclerosis]", La Sclerose en Plaques [Multiple Sclerosis], 9-47 (Rascol et al. eds., 1980).
Hirayama et al., "Serum-Mediated Oligodendrocyte Cytotoxicity in Multiple Sclerosis Patients and Controls", Neurology 1986, vol. 36, pp. 276-278.
Hoffman et al., "Handbook of Clinical Neurology, 12; Viral Diseases", R.R. McKendall, ed., Elsevier Science Publishing, Amsterdam, 1989, pp. 453-466.
Huang, "Defective Interfering Viruses", Fundamental Virology, Fields et al., eds., 1986, pp. 101-117.
Huck et al., "J. of Neurosei", vol. 4, No. 10, pp. 2650-2657, 1984.
A. W. Hugin et al., "A Virus-Encoded Superantigen in a Retrovirus-Induced Immunodeficiency Syndrome of Mice", Science, vol. 252, pp. 424-427, (1991).
James, "Multiple Sclerosis or Blood-Brain Barrier Disease", The Lancet, Jan. 7, 1989, p. 46.
Medline abstract of Jarrett et al., "Studies on vaccination against papillomaviruses: a comparison of purified virus, tumour extract and transformed cells in prophylactic vaccination," Vet Rec 126: 449-452 (1990).
Jervis et al., "Experimental Allergic Encephalomyelitis", J. Neuropathol. Exp. Neurol., 1948; 7, pp. 309-320.
D. Johnson et al., "Quantitation of the Myelin-Associated Glycoprotein in Human Nervous Tissue from Controls and Multiple Sclerosis Patients", Journal of Neurochemistry, vol. 46, No. 4, 1986, pp. 1086-1093.
Johnson, "Viral Aspects of Multiple Sclerosis", Handbook of Clinical Neurology, vol. 3(47): Demyelinating Diseases, 1985, pp. 319-336.
R.T. Johnson, "Nononcogenic Retrovirus Infections as Models for Chronic and Relapsing Human Diseases: Introduction", Reviews of Infectious Diseases, vol. 7, No. 1, Jan.-Feb. 1985, pp. 66-67.
Juntunen et al. "Multiple Sclerosis and Occupational Exposure to Chemicals: A Co-Twin Study of a Nationwide Series of Twins", Br. J. Int. Med., 1989; 46: pp. 417-419.
Karpas et al., "Lack of evidence for involvement of known human retroviruses in multiple sclerosis", Nature, vol. 322, Jul. 10, 1986, pp. 177-178.
Kent et al., "Cerebral Blood Flow, Cerebral Metabolism and Blood-Brain Barrier," Handbook of Clinical Neurology, vol. 56 (12), 1989, pp. 79-91.
H. Koprowski et al., "Multiple sclerosis and human T-cell lymphotropic retroviruses", Nature, vol. 318, Nov. 14, 1985, pp. 154-160.
G. La Mantia et al., "Identification of New Human Repetitive Sequences: Characterization of the Corresponding cDNAs and their Expression in Embryonal Carcinoma Cells", Nucleic Acids Research, vol. 17, No. 15, 5913-5922, (1989).
G. La Mantia et al., "Identification and Characterization of Novel Human Endogenous Retroviral Sequences Prefentially Expressed in Undifferentiated Embryonal Carcinoma Cells", Nucleic Acids Res., 1991, vol. 19, No. 7, pp. 1513-1520.
H. Lassmann et al., "Chronic Relapsing Experimental Allergic Encephalomyelitis-Clinicopathological Comparison with Multiple Sclerosis", Arch Neurol, vol. 36, Aug. 1979, pp. 490-497.
Medline abstract of LEAO, "Tuberculosis: new strategies for the development of diagnostic tests and vaccines," Braz J Med Biol Res 26: 827-833 (1993).
Levi et al., Human Immunodeficiency Coat Protein gp120 Inhibits the .beta.-adrenergic Regulation of Astroglial and Microglial Functions, Proc. Natl. Acad. Sci. USA, vol. 90, Feb. 1993, pp. 1541-1545.
Levine et al., "Conversion of Lytic to Persistent Alphavirus Infection by the bcl-2 Cellular Oncogene", Nature, vol. 361, Feb. 25, 1993, pp. 739-742.
Y.S. Lie et al., Journal of Virology, vol. 38, No. 12, Dec. 1994, pp. 7840-7849, "Chinese hamster ovary cells contain transcriptionally active full length type C provirises".
Linial et al., "Retroviral RNA Packaging: Sequence Requirements and Implications", in Current Topics in Microbiology and Immunobiology. Retroviruses, Strategies of Replication, Swanstrom et al., eds., vol. 157, 1990, pp. 125-152.
R. Lisak et al., "In Vitro Cell-Mediated Immunity of Cerebrospinal-Fluid Lymphocytes to Myelin Basic Protein in Primary Demyelinating Diseases", The New England Journal of Medicine, vol. 297, No. 16, Oct. 20, 1977, pp. 850-853.
Lo et al, "Newly Discovered Mycoplasma Isolated from Patients Infected with HIV", The Lancet, vol. 338, Dec. 7, 1991, pp. 1415-1418.
Lori et al., "Viral DNA Carried by Human Immunodeficiency Virus Type 1 Virions", J. Virol., vol. 66, No. 8, Aug. 1992, pp. 5067-5074.
F. Mallet et al., "Continous RT-PCR and taq DNA Polymerase: Characterization and Comparison to Uncoupled Procedures", Biotechniques, vol. 18, pp. 678-687, 1985.
Mallet et al., "Enzyme-Linked Oligosorbent Assay for Detection of Polymerase Chain Reaction-Amplified Human Immunodeficiency Virus Type I", J. Clin. Microbiol., Jun. 1993, vol. 31, No. 6, pp. 1444-1449.
Marie, "Sclerose en Plaques et Maladies Infectieuses [Multiple Sclerosis and Infectious Diseases]", Le Progres Medical, 1884; 12, pp. 287-289.
P. Marrack et al., "A Maternally Inherited Superantigen Encoded by a Mammary Tumor Virus", Nature, vol. 349, pp. 524-526, (1991).
McDonald, "The Mystery of the Origin of Multiple Sclerosis", J. Neurol. Neurosurg. Psych., 1986; 49, pp. 113-123.
J. Merregaert et al., "Nucleotide Sequence of a Radiation Leukemia Virus Genome", Virology, vol. 158, No. 1, pp. 88-102, (1987).
Meyerhans et al., "Temporal Fluctuations in HIV Quasispecies in Vivo Are Not Reflected by Sequential HIV Isolations", Cell, vol. 58, Sep. 8, 1989, pp. 901-910.
J.D. Mosca et al., "Activation of human immunodeficiency virus by herpesvirus infection: Identification of a region within the long terminal repeat that responds to a trans-acting factor encoded by herpes simplex virus 1", Proceedings of the National Academy of Sciences of USA, vol. 84, No. 21, Nov. 1987, pp. 7408-7412.
Mosmann, "Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays", Journal of Immunological Methods, 65, 1983, pp. 55-63.
O. Narayan et al., "Lentiviral Diseases of Sheep and Goats: Chronic Pneumonia Leukoencephalomyelitis, and Arthritis", Reviews of Infectious Diseases, vol. 7, No. 1, Jan.-Feb. 1985, pp. 89-98.
N. Nathanson et al., "Experimental Visna in Icelandic Sheep: The Prototype Lentiviral Infection", Reviews of Infectious Diseases, vol. 7, No. 1, Jan.-Feb. 1985, pp. 75-82.
Newell et al., "Ligation of Major Histocompatibility Complex Class II Molecules Mediates Apoptotic Cell Death in Resting B Lymphocytes", Proc. Natl. Adac. Sci. USA, vol. 90, Nov. 1993, pp. 10459-10463.
Nielsen et al., "Sequence-Selective Recognition of DNA by Strand Displacement with a Thymine-Substituted Polyamide", Science, vol. 254, pp. 1497-1500.
Norby, "Viral Antibodies in Multiple Sclerosis", Prog. Med. Virol., vol. 24 1978, pp. 1-39 (1978).
M. Ohta et al., "Sera from Patients with Multiple Sclerosis React with Human T Cell Lymphotropic Virus-I Gag Proteins but not Env Proteins--Western Blotting Analysis", The Journal of Immunology, vol. 137, No. 11, Dec. 1, 1986, pp. 3440-3443.
Medline abstract of Orlandi et al., "Characterization of the 175-kilodalton erythrocyte binding antigen of Plasmodium falciparum," Mol Biochem Parasitol 40: 285-294 (1990).
Ostrove et al., "Activation of the Human Innumodeficiency Virus by Herpes Simplex Virus Type 1", J Virol 61(12), Dec. 1987, pp. 3726-3732.
M. Palmarini, "The Exogenous Form of Jaagsiekte Retrovirus is Specifically Associated with a contagious Lung Cancer of Sheet", J. Virol, vol. 70, pp. 1618-1623, (1996).
J.L. Pablos et al., "A novel retroviral POL sequence is present in patients with rheumatoid arthritis", & American College of Rheumatology 57th Annual Scientific Meeting, Nov. 7-11, 1993 San Antonio, Texas, USA, Arthritis and Rheumatism, vol. 36, No. 9 supl. 1993, p. S55, Abstract No. 102.
Medline abstract of Pei et al., "Identification, purification, and characterization of major antigenic proteins of Campylobacter jejuni," J Biol Chem 266: 16363-16369 (1991).
H. Perron et al., "Isolations of an Unknown Retrovirus from CSF, Blood and Brain Cells of Patients with Multiple Sclerosis", in Current Concepts in Multiple Sclerosis, Wietholter et al., eds., 1991, Elsevier publ., pp. 111-116.
H. Perron et al., "Leptomeningeal cell line from multiple sclerosis with reverse transcriptase activity and viral particles", Res. Virol., Nov. 1989, vol. 140(6), pp. 551-561.
H. Perron et al., "Leptomeningeal cell line from multiple sclerosis with reverse transcriptase activity and viral particles", Biological Abstracts, vol. 89, No. 9, May 1, 1990.
H. Perron et al., "Isolation of Retrovirus from Patients with Multiple Sclerosis", The Lancet, vol. 337, No. 8745, Apr. 6, 1991, pp. 862-863.
H. Perron et al., "Antibody to Reverse Transcriptase of Human Retrovirus in Multiple Sclerosis", Biological Abstracts, vol. 93, No. 6, Mar. 15, 1992.
H. Perron et al., "Herpes simplex virus ICPO and ICP4 immediate early proteins strongly enhance expression of a retrovirus harboured by a leptomeningeal cell line from a patient with multiple sclerosis", The Journal of General Virology, vol. 74, No. 1, Jan. 1993, pp. 65-72.
H. Perron et al., "Retrovirus Isolation from Patients with Multiple Sclerosis: Epiphenomenon or Causative Factor?", AIDS Research and Human Retroviruses, vol. 8, No. 5, May 1992, p. 922.
H. Perron et al., "In Vitro Transmission and Antigenicity of a Retrovirus Isolated from a Multiple Sclerosis Patient", Res. Virol., vol. 143, No. 5, 1992, pp. 337-350.
Perron et al., "Retroviral Reactivation by Herpesviruses in MS: Serological Arguments", Current Concepts in Multiple Sclerosis 1991, pp. 331-332.
A. Plaza et al., Theofilopoulos, A.N. New Human v.beta. 12DD Genes and Polymorphic Variants. J. Imm; vol. 147, No. 12, pp. 4360-4365, 1991.
Poirier et al., "La Barriere Hemato-Encephalique. Donnees Morphologiques [The Blood-Brain Barrier. Morphological Data]", La Revue de Medecine Interne, vol. IV, No. 2, Jun. 1983, pp. 131-144.
J. L. Portis, Wild Mouse Retrovirus: Pathogenesis in "Retrovirus Infections of the Nervous System". Oldstone M.B.A. and Koprowsky H. Eds. Current topics in microbiology and immunology, n.degree.160, pp. 11-27, (Springer-Verlag, Berlin, 1990).
C.M. Poser et al., "New Diagnostic Criteria for Multiple Sclerosis: Guidelines for Research Protocols, in The diagnosis of Multiple Sclerosis", Thieme Stratton Inc., pp. 225-229, 1984.
D.N., Posnet, "Do Superantigens Play a Role in Autoimmunity?", Semin. Immunol., vol. 5, pp. 65-72, 1993.
Prineas, "The Neuropathology of Multiple Sclerosis", Handbook of Clinical Neurology, vol. 3 (47), 1985, pp. 213-257.
Prineas et al., "Multiple Sclerosis: Remyelination of Nascent Lesions", Annals of Neurology, vol. 33, No. 2, Feb. 1993, pp. 137-151.
Prineas, "Pathology of the Early Lesion in Multiple Sclerosis", Human Pathology, vol. 6, No. 5, Sep. 1975, pp. 531-554.
Prineas et al., "Macrophages, Lymphocytes, and Plasma Cells in the Perivascular Compartment in Chronic Multiple Sclerosis", Laboratory Investigation, vol. 38, No. 4, 1978, pp. 409-421.
Ransohoff et al., "Heat-Shock Proteins and Autoimmunity: Implications for Multiple Sclerosis", Annals of Neurology, vol. 34, No. 1, Jul. 1993, pp. 5-7.
Rapoport, Blood-Brain Barrier in Physiology and Medicine, 129 (1976).
E.P. Reddy et al., "Amplification and Molecular Cloning of HTLV-I Sequences from DNA of Multiple Sclerosis Patients", Science, vol. 243, Jan. 27, 1989, pp. 529-533.
S. S. Rhee et al., "A single Amino Acid Substitution Within the Matrix Protein of a D-Type Retrovirus Converts Its Morphogenesis to that of a C-Type Retrovirus", Cell 63, pp. 77-86, (1990).
Riise et al., "Clustering of Residence of Multiple Sclerosis Patients at Age 13 to 20 Years in Hordaland, Norway", Am J Epidemiol 1991, vol. 133, No. 9, pp. 932-939.
Robbins et al., "Production of Cytotoxic Factor for Oligodendrocytes by Stimulated Astrocytes", The Journal of Immunology, vol. 139, No. 8, Oct. 15, 1987, pp. 2593-2597.
Rosati et al., "Incidence of Multiple Sclerosis in the Town of Sassari, Sardinia, 1965 to 1985: Evidence for Increasing Occurrence of the Disease", Neurology 38 (Mar. 1988), pp. 384-388.
Rudge, "Does a Retrovirally Encoded Superantigen Cause Multiple Sclerosis?", J. Neurology Neurosurgery & Psychiatry 1991, vol. 54, pp. 853-855.
Medline abstract of Rumschlag et al., "Immunologic characterization of a 35-kilodalton recombinant antigen of Mycobacterium tuberculosis," J Clin Microbiol 28: 591-595 (1990).
Medline abstract of Sakulramrung et al., "Antigenic and immunogenic characteristics of subcellular fractions and whole cells of a rough E. coli 0111 (J5) mutant," Immunobiology 169: 372-388 (1985).
Selmaj, et al., "Tumor Necrosis Factor Mediates Myelin and Oligodendrocyte Damage In Vitro", Annals of Neurology, vol. 23, No. 4, Apr. 1988, pp. 339-346.
Shih et al., "Detection of MUltiple, Novel Reverse Transcriptase Coding Sequences in Human Nucleic Acids: Relation to Primate Retroviruses", J. Virol., Jan. 1989, vol. 63, No. 1, pp. 64-75.
Silberberg et al., "Tissue Culture Demyelination by Normal Human Serum", Annals of Neurology, vol. 15, No. 6, Jun. 1994, pp. 575-580.
M. Sommerlund et al., "Retrovirus-like particles in an Epstein-Barr virus-producing cell line derived from a patient with chronic progressive myelopathy", Acta Neurol Scand, 1993: 87: pp. 71-76.
P. Sonigo et al., "Nucleotide Sequence of Mason-Pfizer Monkey Virus: An immunosuppressive D-Type Retrovirus", Cell 45, pp. 375-385, (1986).
Southern, "Detection of Specific Sequences Among DNA Fragments Separated by Gel Electrophoresis", J. Mol. Biol., 1975, vol. 98, pp. 503-517.
Suzumura et al., "Serum Cytotoxicity to Oligodendrocytes in Multiple Sclerosis and Controls: Assessment by .sup.51 Cr Release Assay", J. Neuroimmunol., 11 (1986), pp. 137-147.
Traugott, "Multiple Sclerosis: Relevance of Class I and Class II MHC-Expressing Cells to Lesion Development", Journal of Neuroimmunology, 16, 1987, pp. 283-302.
Waksman, "Mechanisms in Multiple Sclerosis", Nature, vol. 318, Nov. 14, 1985, pp. 104-105.
K.G. Warren et al., "Diagnostic Value of Cerebrospinal Fluid Anti-Myelin Basic Protein in Patients with Multiple Sclerosis", Annals of Neurology, vol. 20, No. 1, Jul. 1986, pp. 20-25.
Williams et al., "Molecular Regulation of Apoptosis: Genetic Controls on Cell Death", Cell, vol. 74, Sep. 10, 1993, pp. 777-779.
Wienfield et al., "Stress Proteins, Autoimmunity, and Autoimmune Disease", Current Topics in Microbiology and Immunology, vol. 167, Springer-Verlag, Berlin, 1991, pp. 161-189.
D. L. Wilkinson et al., "Evidence for a functional subclass of the RTLV-H family of human endogenous retrovirus-like sequences", J. Virol., vol. 67, pp. 2981-2989, (1993).
Wollinsky et al., "Liquorpherese bei 10 Patienten mit Multipler Sklerose [Fluid Phoresis in 10 Patients With Multiple Sclerosis]", Verhandlungen der Deutschen Gesellschaft fur Neurologie, vol. 7, 1992, pp. 444-445.
Woodland, et al., "An Endogenous Retrovirus Mediating Deletion of .alpha..beta. T cells?", Nature, vol. 349, Feb. 7, 1991, pp. 529-530.
Takeuchi, 1994, vol. 69(4) p. 821-835. (Abstract only) Hakkaido IgKu Zasshi.
Boswelt et al, 1988, Oxford Press, p. 161-178.

PATENT CLAIMS We claim:

1. An isolated, purified or synthesized nucleotide sequence comprising a sequence selected from the group consisting of:

SEQ ID NO:46, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:89, and

a complementary sequence complementary to one of said SEQ ID NO:46, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61 or SEQ ID NO:89.
PATENT DESCRIPTION Multiple sclerosis (MS) is a demyelinating disease of the central nervous system (CNS) the cause of which remains as yet unknown.

Many studies have supported the hypothesis of a viral aetiology of the disease, but none of the known viruses tested has proved to be the causal agent sought: a review of the viruses sought for several years in MS has been compiled by E. Norrby (1) and R. T. Johnson (2).

Recently, a retrovirus different from the known human retroviruses has been isolated in patients suffering from MS (3, 4, and 5). The authors were also able to show that this retrovirus could be transmitted in vitro, that patients suffering from MS produced antibodies capable of recognizing proteins associated with the infection of leptomeningeal cells by this retrovirus, and that the expression of the latter could be strongly stimulated by the immediate-early genes of some herpes-viruses (6).

All these results point to the role in MS of at least one unknown retrovirus or of a virus having reverse transcriptase activity which is detectable according to the method published by H. Perron (3) and qualified as "LM7-like RT" activity. The content of the publication identified by (3) is incorporated in the present description by reference.

Recently, the Applicant's studies have enabled two continuous cell lines infected with natural isolates originating from two different patients suffering from MS to be obtained by a culture method as described in the document WO-A-93/20188, the content of which is incorporated in the present description by reference. These two lines, derived from human choroid plexus cells, designated LM7PC and PLI-2, were deposited with the ECACC on Jul. 22, 1992 and Jan. 8, 1993, respectively, under numbers 92072201 and 93010817, in accordance with the provisions of the Budapest Treaty. Moreover, the viral isolates possessing LM7-like RT activity were also deposited with the ECACC under the overall designation of "strains". The "strain" or isolate harboured by the PLI-2 line, designated POL-2, was deposited with the ECACC on Jul. 22, 1992 under No. V92072202. The "strain" or isolate harboured by the LM7PC line, designated MS7PG, was deposited with the ECACC on Jan. 8, 1993 under No. V93010816.

Starting from the cultures and isolates mentioned above, characterized by biological and morphological criteria, the next step was to endeavour to characterize the nucleic acid material associated with the viral particles produced in these cultures.

The portions of the genome which have already been characterized have been used to develop tests for molecular detection of the viral genome and immunoserological tests, using the amino acid sequences encoded by the nucleotide sequences of the viral genome, in order to detect the immune response directed against epitopes associated with the infection and/or viral expression.

These tools have already enabled an association to be confirmed between MS and the expression of the sequences identified in the patents cited later. However, the viral system discovered by the Applicant is related to a complex retroviral system. In effect, the sequences to be found encapsidated in the extracellular viral particles produced by the different cultures of cells of patients suffering from MS show clearly that there is coencapsidation of retroviral genomes which are related but different from the "wild-type" retroviral genome which produces the infective viral particles. This phenomenon has been observed between replicative retroviruses and endogenous retroviruses belonging to the same family, or even heterologous retroviruses. The notion of endogenous retroviruses is very important in the context of our discovery since, in the case of MSRV-1, it has been observed that endogenous retroviral sequences comprising sequences homologous to the MSRV-1 genome exist in normal human DNA. The existence of endogenous retroviral elements (ERV) related to MSRV-1 by all or part of their genome explains the fact that the expression of the MSRV-1 retrovirus in human cells is able to interact with closely related endogenous sequences. These interactions are to be found in the case of pathogenic and/or infectious endogenous retroviruses (for example some ecotropic strains of the murine leukaemia virus), and in the case of exogenous retroviruses whose nucleotide sequence may be found partially or wholly, in the form of ERVs, in the host animal's genome (e.g. mouse exogenous mammary tumor virus transmitted via the milk). These interactions consist mainly of (i) a trans-activation or coactivation of ERVs by the replicative retrovirus (ii) and "illegitimate" encapsidation of RNAs related to ERVS, or of ERVs--or even of cellular RNAs--simply possessing compatible encapsidation sequences, in the retroviral particles produced by the expression of the replicative strain, which are sometimes transmissible and sometimes with a pathogenicity of their own, and (iii) more or less substantial recombinations between the coencapsidated genomes, in particular in the phases of reverse transcription, which lead to the formation of hybrid genomes, which are sometimes transmissible and sometimes with a pathogenicity of their own.

Thus, (i) different sequences related to MSRV-1 have been found in the purified viral particles; (ii) molecular analysis of the different regions of the MSRV-1 retroviral genome should be carried out by systematically analyzing the coencapsidated, interfering and/or recombined sequences which are generated by the infection and/or expression of MSRV-1; furthermore, some clones may have defective sequence portions produced by the retroviral replication and template errors and/or errors of transcription of the reverse transcriptase; (iii) the families of sequences related to the same retroviral genomic region provide the means for an overall diagnostic detection which may be optimized by the identification of invariable regions among the clones expressed, and by the identification of reading frames responsible for the production of antigenic and/or pathogenic polypeptides which may be produced only by a portion, or even by just one, of the clones expressed, and, under these conditions, the systematic analysis of the clones expressed in the region of a given gene enables the frequency of variation and/or of recombination of the MSRV-1 genome in this region to be evaluated and the optimal sequences for the applications, in particular diagnostic applications, to be defined; (iv) the pathology caused by a retrovirus such as MSRV-1 may be a direct effect of its expression and of the proteins or peptides produced as a result thereof, but also an effect of the activation, the encapsidation or the recombination of related or heterologous genomes and of the proteins or peptides produced as a result thereof; thus, these genomes associated with the expression of and/or infection by MSRV-1 are an integral part of the potential pathogenicity of this virus, and hence constitute means of diagnostic detection and special therapeutic targets. Similarly, any agent associated with or cofactor of these interactions responsible for the pathogenesis in question, such as MSRV-2 or the glyotoxic factor which are described in the patent application published under No. FR-2,716,198, may participate in the development of an overall and very effective strategy for the diagnosis, prognosis, therapeutic monitoring and/or integrated therapy of MS in particular, but also of any other disease associated with the same agents.

In this context, a parallel discovery has been made in another autoimmune disease, rheumatoid arthritis (RA), which has been described in the French Patent Application filed under No. 95/02960. This discovery shows that, by applying methodological approaches similar to the ones which were used in the Applicant's work on MS, it was possible to identify a retrovirus expressed in RA which shares the sequences described for MSRV-1 in MS, and also the coexistence of an associated MSRV-2 sequence also described in MS. As regards MSRV-1, the sequences detected in common in MS and RA relate to the pol and gag genes. In the current state of knowledge, it is possible to associate the gag and pol sequences described with the MSRV-1 strains expressed in these two diseases.

The present patent application relates to various results which are additional to those already protected by the following French Patent Applications:

No. 92/04322 of 03.04.1992, published under No. 2,689,519;

No. 92/13447 of 03.11.1992, published under No. 2,689,521;

No. 92/13443 of 03.11.1992, published under No. 2,689,520;

No. 94/01529 of 04.02.1994, published under No. 2,715,936;

No. 94/01531 of 04.02.1994, published under No. 2,715,939;

No. 94/01530 of 04.02.1994, published under No. 2,715,936;

No. 94/01532 of 04.02.1994, published under No. 2,715,937;

No. 94/14322 of 24.11.1994, published under No. 2,727,428;

and No. 94/15810 of 23.12.1994; published under No. 2,728,585.

The present invention relates, in the first place, to a viral material, in the isolated or purified state, which may be recognized or characterized in different ways:

its genome comprises a nucleotide sequence chosen from the group including the sequences SEQ ID NO:46, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:89, their complementary sequences and their equivalent sequences, in particular nucleotide sequences displaying, for any succession of 100 contiguous monomers, at least 50% and preferably at least 70% homology with the said sequences SEQ ID NO:46, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60 SEQ ID NO:61, SEQ ID NO:89, respectively, and their complementary sequences;

the region of its genome comprising the env and pol genes and a portion of the gag gene, excluding the subregion having a sequence identical or equivalent to SEQ ID NO:1, codes for any polypeptide displaying, for any contiguous succession of at least 30 amino acids, at least 50% and preferably at least 70% homology with a peptide sequence encoded by any nucleotide sequence chosen from the group including SEQ ID NO:46, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60 SEQ ID NO:61 SEQ ID NO:89 and their complementary sequences;

the pol gene comprises a nucleotide sequence partially or totally identical or equivalent to SEQ ID NO:57, excluding SEQ ID NO:1.

the gag gene comprises a nucleotide sequence partially or totally identical or equivalent to SEQ ID NO:88.

As indicated above, according to the present invention, the viral material as defined above is associated with MS. And as defined by reference to the pol or gag gene of MSRV-1, and more especially to the sequences SEQ ID NOS 51, 56, 57, 59, 60, 61, 88 and 89, this viral material is associated with RA.

The present invention also relates to different nucleotide fragments each comprising a nucleotide sequence chosen from the group including:

(a) all the genomic sequences, partial and total, of the pol gene of the MSRV-1 virus, except for the total sequence of the nucleotide fragment defined by SEQ ID NO:1;

(b) all the genomic sequences, partial and total, of the env gene of MSRV-1;

(c) all the partial genomic sequences of the gag gene of MSRV-1;

(d) all the genomic sequences overlapping the pol gene and the env gene of the MSRV-1 virus, and over-lapping the pol gene and the gag gene;

(e) all the sequences, partial and total, of a clone chosen from the group including the clones FBd3 (SEQ ID NO:46), t pol (SEQ ID NO:51), JLBc1 (SEQ ID NO:52), JLBc2 (SEQ ID NO:53) and GM3 (SEQ ID NO:56), FBd13 (SEQ ID NO:58), LB19 (SEQ ID NO:59), LTRGAG12 (SEQ ID NO:60), FP6 (SEQ ID NO:61), G+E+A (SEQ ID NO:89), excluding any nucleotide sequence identical to or lying within the sequence defined by SEQ ID NO:1;

(f) sequences complementary to the said genomic sequences;

(g) sequences equivalent to the said sequences (a) to (e), in particular nucleotide sequences displaying, for any succession of 100 contiguous monomers, at least 50% and preferably at least 70% homology with the said sequences (a) to (d).

provided that this nucleotide fragment does not comprise or consist of the sequence ERV-9 as described in LA MANTIA et al. (18).

The term genomic sequences, partial or total, includes all sequences associated by coencapsidation or by coexpression, or recombined sequences.

Preferably, such a fragment comprises:

either a nucleotide sequence identical to a partial or total genomic sequence of the pol gene of the MSRV-1 virus, except for the total sequence of the nucleotide fragment defined by SEQ ID NO:1, or identical to any sequence equivalent to the said partial or total genomic sequence, in particular one which is homologous to the latter;

or a nucleotide sequence identical to a partial or total genomic sequence of the env gene of the MSRV-1 virus, or identical to any sequence complementary to the said nucleotide sequence, or identical to any sequence equivalent to the said nucleotide sequence, in particular one which is homologous to the latter.

In particular, the invention relates to a nucleotide fragment comprising a coding nucleotide sequence which is partially or totally identical to a nucleotide sequence chosen from the group including:

the nucleotide sequence defined by SEQ ID NO:40, SEQ ID NO:62 or SEQ ID NO:89;

sequences complementary to SEQ ID NO:40, SEQ ID NO:62 or SEQ ID NO:89;

sequences equivalent, and in particular homologous to SEQ ID NO:40, SEQ ID NO:62 or SEQ ID NO:89;

sequences coding for all or part of the peptide sequence defined by SEQ ID NO:39, SEQ ID NO:63 or SEQ ID NO:90;

sequences coding for all or part of a peptide sequence equivalent, in particular homologous to SEQ ID NO:39, SEQ ID NO:63 or SEQ ID NO:90, which is capable of being recognized by sera of patients infected with the MSRV-1 virus, or in whom the MSRV-1 virus has been reactivated.

The invention also relates to any nucleic acid probe for detection of a pathogenic and/or infective agent associated with MS, which is capable of hybridizing specifically with any fragment such as is defined above, belonging or lying within the genome of the said pathogenic agent. It relates, in addition, to any nucleic acid probe for detection of a pathogenic and/or infective agent associated with RA, which is capable of hybridizing specifically with any fragment as defined above by reference to the pol and gag genes, and especially with respect to the sequences SEQ ID NOS 40, 51, 56, 59, 60, 61, 62, 89 and SEQ ID NOS 39, 63 and 90.

The invention also relates to a primer for the amplification by polymerization of an RNA or a DNA of a viral material, comprising a nucleotide sequence identical or equivalent to at least one portion of the nucleotide sequence of any fragment such as is defined above, in particular a nucleotide sequence displaying, for any succession of 10 contiguous monomers, at least 70% homology with at least the said portion of the said fragment. Preferably, the nucleotide sequence of such a primer is identical to any one of the sequences chosen from the group including SEQ ID NO:47 to SEQ ID NO:50, SEQ ID NO:55 and SEQ ID NO:64 SEQ ID NO:86.

Generally speaking the invention also encompasses any RNA or DNA, and in particular replication vector, comprising a genomic fragment of the viral material such as is defined above, or a nucleotide fragment such as is defined above.

The invention also relates to the different peptides encoded by any open reading frame belonging to a nucleotide fragment such as is defined above, in particular any polypeptide, for example any oligopeptide forming or comprising an antigenic determinant recognized by sera of patients infected with the MSRV-1 virus and/or in whom the MSRV-1 virus has been reactivated. Preferably, this polypeptide is antigenic, and is encoded by the open reading frame beginning, in the 5'-3' direction, at nucleotide 181 and ending at nucleotide 330 of SEQ ID NO:1.

In particular, the invention relates to an antigenic polypeptide recognized by the sera of patients infected with the MSRV-1 virus, and/or in whom the MSRV-1 virus has been reactivated, whose peptide sequence is partially or totally identical or is equivalent to the sequence defined by SEQ ID NO:39, SEQ ID NO:63 and SEQ ID NO:87; such a sequence is identical, for example, to any sequence chosen from the group including the sequences SEQ ID NO:41 to SEQ ID NO:44, SEQ ID NO:63 and SEQ ID NO:87.

The present invention also proposes mono- or polyclonal antibodies directed against the MSRV-1 virus, which are obtained by the immunological reaction of a human or animal body to an immunogenic agent consisting of an antigenic polypeptide such as is defined above.

The invention next relates to:

reagents for detection of the MSRV- virus, or of an exposure to the latter, comprising, as reactive substance, a peptide, in particular an antigenic peptide, such as is defined above, or an anti-ligand, in particular an antibody to the said peptide;

all diagnostic, prophylactic or therapeutic compositions comprising one or more peptides, in particular antigenic peptides, such as are defined above, or one or more anti-ligands, in particular antibodies to the peptides, discussed above; such a composition is preferably, and by way of example, a vaccine composition.

The invention also relates to any diagnostic, prophylactic or therapeutic composition, in particular for inhibiting the expression of at least one pathogenic and/or infective agent associated with MS comprising a nucleotide fragment such as is defined above or a polynucleotide, in particular oligonucleotide, whose sequence is partially identical to that of the said fragment, except for that of the fragment having the nucleotide sequence SEQ ID NO:1. Likewise, it relates to any diagnostic, prophylactic or therapeutic composition, in particular for inhibiting the expression of at least one pathogenic and/or infective agent associated with RA, comprising a nucleotide fragment such as is defined above by reference to the pol and gag genes, and especially with respect to the sequences SEQ ID NOS 40, 51, 56, 59, 60, 61, 62 and 89.

According to the invention, these same fragments or polynucleotides, in particular oligonucleotides, may participate in all suitable compositions for detecting, according to any suitable process or method, a pathological and/or infective agent associated with MS and with RA, respectively, in a biological sample. In such a process, an RNA and/or a DNA presumed to belong or originating from the said pathological and/or infective agent, and/or their complementary RNA and/or DNA, is/are brought into contact with such a composition.

The present invention also relates to any process for detecting the presence or exposure to such a pathological and/or infective agent, in a biological sample, by bringing this sample into contact with a peptide, in particular an antigenic peptide such as is defined above, or an anti-ligand, in particular an anti-body to this peptide, such as is defined above.

In practice, and for example, a device for detection of the MSRV-1 virus comprises a reagent such as is defined above, supported by a solid support which is immunologically compatible with the reagent, and a means for bringing the biological sample, for example a sample of blood or of cerebrospinal fluid, likely to contain anti-MSRV-1 antibodies, into contact with this reagent under conditions permitting a possible immunological reaction, the foregoing items being accompanied by means for detecting the immune complex formed with this reagent.

Lastly, the invention also relates to the detection of anti-MSRV-1 antibodies in a biological sample, for example a sample of blood or of cerebrospinal fluid, according to which this sample is brought into contact with a reagent such as is defined above, consisting of an antibody, under conditions permitting their possible immunological reaction, and the presence of the immune complex thereby formed with the reagent is then detected.

Before describing the invention in detail, different terms used in the description and the claims are now defined:

strain or isolate is understood to mean any infective and/or pathogenic biological fraction containing, for example, viruses and/or bacteria and/or parasites, generating pathogenic and/or antigenic power, harboured by a culture or a living host; as an example, a viral strain according to the above definition can contain a coinfective agent, for example a pathogenic protist,

the term "MSRV" used in the present description denotes any pathogenic and/or infective agent associated with MS, in particular a viral species, the attenuated strains of the said viral species or the defective-interfering particles or particles containing coencapsidated genomes, or alternatively genomes recombined with a portion of the MSRV-1 genome, derived from this species. Viruses, and especially viruses containing RNA, are known to have a variability resulting, in particular, from relatively high rates of spontaneous mutation (7), which will be borne in mind below for defining the notion of equivalence,

human virus is understood to mean a virus capable of infecting, or of being harboured by human beings,

in view of all the natural or induced variations and/or recombination which may be encountered when implementing the present invention, the subjects of the latter, defined above and in the claims, have been expressed including the equivalents or derivatives of the different biological materials defined below, in particular of the homologous nucleotide or peptide sequences,,

the variant of a virus or of a pathogenic and/or infective agent according to the invention comprises at least one antigen recognized by at least one antibody directed against at least one corresponding antigen of the said virus and/or said pathogenic and/or infective agent, and/or a genome any part of which is detected by at least one hybridization probe and/or at least one nucleotide amplification primer specific for the said virus and/or pathogenic and/or infective agent, such as, for example, for the MSRV-1 virus, the primers and probes having a nucleotide sequence chosen from SEQ ID No. 20 to SEQ ID No. 24, SEQ ID No. 26, SEQ ID No. 16 to SEQ ID No. 19, SEQ ID No. 31 to SEQ ID No. 33, SEQ ID No. 45, SEQ ID No. 47, SEQ ID No. 48, SEQ ID No. 49, SEQ ID No. 50, SEQ ID No. 45 and their complementary sequences, under particular hybridization conditions well known to a person skilled in the art,

according to the invention, a nucleotide fragment or an oligonucleotide or polynucleotide is an arrangement of monomers, or a biopolymer, characterized by the informational sequence of the natural nucleic acids, which is capable of hybridizing with any other nucleotide fragment under predetermined conditions, it being possible for the arrangement to contain monomers of different chemical structures and to be obtained from a molecule of natural nucleic acid and/or by genetic recombination and/or by chemical synthesis; a nucleotide fragment may be identical to a genomic fragment of the MSRV-1 virus discussed in the present invention, in particular a gene of this virus, for example pol or env in the case of the said virus,

thus, a monomer can be a natural nucleotide of nucleic acid whose constituent elements are a sugar, a phosphate group and a nitrogenous base; in RNA the sugar is ribose, in DNA the sugar is 2-deoxyribose; depending on whether the nucleic acid is DNA or RNA, the nitrogenous base is chosen from adenine, guanine, uracil, cytosine and thymine; or the nucleotide can be modified in at least one of the three constituent elements; as an example, the modification can occur in the bases, generating modified bases such as inosine, 5-methyldeoxy-cytidine, deoxyuridine, 5-(dimethylamino)deoxyuridine, 2,6-diaminopurine, 5-bromodeoxyuridine and any other modified base promoting hybridization; in the sugar, the modification can consist of the replacement of at least one deoxyribose by a polyamide (8), and in the phosphate group, the modification can consist of its replacement by esters chosen, in particular, from diphosphate, alkyl- and arylphosphonate and phosphorothioate esters,

"informational sequence" is understood to mean any ordered succession of monomers whose chemical nature and order in a reference direction constitute or otherwise an item of functional information of the same quality as that of the natural nucleic acids,

hybridization is understood to mean the process during which, under suitable working conditions, two nucleotide fragments having sufficiently complementary sequences pair to form a complex structure, in particular double or triple, preferably in the form of a helix,

a probe comprises a nucleotide fragment synthesized chemically or obtained by digestion or enzymatic cleavage of a longer nucleotide fragment, comprising at least six monomers, advantageously from 10 to 100 monomers and preferably 10 to 30 monomers, and possessing a specificity of hybridization under particular conditions; preferably, a probe possessing fewer than 10 monomers is not used alone, but is used in the presence of other probes of equally short size or otherwise; under certain special conditions, it may be useful to use probes of size greater than 100 monomers; a probe may be used, in particular, for diagnostic purposes, such molecules being, for example, capture and/or detection probes,

the capture probe may be immobilized on a solid support by any suitable means, that is to say directly or indirectly, for example by covalent bonding or passive adsorption,

the detection probe may be labelled by means of a label chosen, in particular, from radioactive isotopes, enzymes chosen, in particular, from peroxidase and alkaline phosphatase and those capable of hydrolysing a chromogenic, fluorogenic or luminescent substrate, chromophoric chemical compounds, chromogenic, fluorogenic or luminescent compounds, nucleotide base analogues and biotin,

the probes used for diagnostic purposes of the invention may be employed in all known hybridization techniques, and in particular the techniques termed "DOT-BLOT" (9), "SOUTHERN BLOT" (10), "NORTHERN BLOT", which is a technique identical to the "SOUTHERN BLOT" technique but which uses RNA as target, and the SANDWICH technique (11); advantageously, the SANDWICH technique is used in the present invention, comprising a specific capture probe and/or a specific detection probe, on the understanding that the capture probe and the detection probe must possess an at least partially different nucleotide sequence,

any probe according to the present invention can hybridize in vivo or in vitro with RNA and/or with DNA in order to block the phenomena of replication, in particular translation and/or transcription, and/or to degrade the said DNA and/or RNA,

a primer is a probe comprising at least six monomers, and advantageously from 10 to 30 monomers, possessing a specificity of hybridization under particular conditions for the initiation of an enzymatic polymerization, for example in an amplification technique such as PCR (polymerase chain reaction), in an elongation process such as sequencing, in a method of reverse transcription or the like,

two nucleotide or peptide sequences are termed equivalent or derived with respect to one another, or with respect to a reference sequence, if functionally the corresponding biopolymers can perform substantially the same role, without being identical, as regards the application or use in question, or in the technique in which they participate; two sequences are, in particular, equivalent if they are obtained as a result of natural variability, in particular spontaneous mutation of the species from which they have been identified, or induced variability, as are two homologous sequences, homology being defined below,

"variability" is understood to mean any spontaneous or induced modification of a sequence, in particular by substitution and/or insertion and/or deletion of nucleotides and/or of nucleotide fragments, and/or extension and/or shortening of the sequence at one or both ends; an unnatural variability can result from the genetic engineering techniques used, for example the choice of synthesis primers, degenerate or otherwise, selected for amplifying a nucleic acid; this variability can manifest itself in modifications of any starting sequence, considered as reference, and capable of being expressed by a degree of homology relative to the said reference sequence,

homology characterizes the degree of identity of two nucleotide or peptide fragments compared; it is measured by the percentage identity which is determined, in particular, by direct comparison of nucleotide or peptide sequences, relative to reference nucleotide or peptide sequences,

this percentage identity has been specifically determined for the nucleotide fragments, clones in particular, dealt with in the present invention, which are homologous to the fragments identified, for the MSRV-1 virus, by SEQ ID No. 1 to No. 9, SEQ ID NO:46, SEQ ID NO:51 to SEQ ID NO:53, SEQ ID NO:40, SEQ ID NO:56 and SEQ ID NO:57, as well as for the probes and primers homologous to the probes and primers identified by SEQ ID NO:20 to SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:16 to SEQ ID NO:19, SEQ ID NO:31 to SEQ ID NO:33, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:55, SEQ ID NO:40, SEQ ID NO:56 and SEQ ID NO:57; as an example, the smallest percentage identity observed between the different general consensus sequences of nucleic acids obtained from fragments of MSRV-1 viral RNA, originating from the LM7PC and PLI-2 lines according to a protocol detailed later, is 67% in the region described in FIG. 1,

any nucleotide fragment is termed equivalent or derived from a reference fragment if it possesses a nucleotide sequence equivalent to the sequence of the reference fragment; according to the above definition, the following in particular are equivalent to a reference nucleotide fragment:

a) any fragment capable of hybridizing at least partially with the complement of the reference fragment,

b) any fragment whose alignment with the reference fragment results in the demonstration of a larger number of identical contiguous bases than with any other fragment originating from another taxonomic group,

c) any fragment resulting, or capable of resulting, from the natural variability of the species from which it is obtained,

d) any fragment capable of resulting from the genetic engineering techniques applied to the reference fragment,

e) any fragment containing at least eight contiguous nucleotides encoding a peptide which is homologous or identical to the peptide encoded by the reference fragment,

f) any fragment which is different from the reference fragment by insertion, deletion or substitution of at least one monomer, or extension or shortening at one or both of its ends; for example, any fragment corresponding to the reference fragment flanked at one or both of its ends by a nucleotide sequence not coding for a polypeptide,

polypeptide is understood to mean, in particular, any peptide of at least two amino acids, in particular an oligopeptide or protein, extracted, separated or substantially isolated or synthesized through human intervention, in particular those obtained by chemical synthesis or by expression in a recombinant organism,

polypeptide partially encoded by a nucleotide fragment is understood to mean a polypeptide possessing at least three amino acids encoded by at least nine contiguous monomers lying within the said nucleotide fragment,

an amino acid is termed analogous to another amino acid when their respective physicochemical properties, such as polarity, hydrophobicity and/or basicity and/or acidity and/or neutrality are substantially the same; thus, a leucine is analogous to an isoleucine.

any polypeptide is termed equivalent or derived from a reference polypeptide if the polypeptides compared have substantially the same properties, and in particular the same antigenic, immunological, enzymological and/or molecular recognition properties; the following in particular are equivalent to a reference polypeptide:

a) any polypeptide possessing a sequence in which at least one amino acid has been replaced by an analogous amino acid,

b) any polypeptide having an equivalent peptide sequence, obtained by natural or induced variation of the said reference polypeptide and/or of the nucleotide fragment coding for the said polypeptide,

c) a mimotope of the said reference polypeptide,

d) any polypeptide in whose sequence one or more amino acids of the L series are replaced by an amino acid of the D series, and vice versa,

e) any polypeptide into whose sequence a modification of the side chains of the amino acids has been introduced, such as, for example, an acetylation of the amine functions, a carboxylation of the thiol functions, an esterification of the carboxyl functions,

f) any polypeptide in whose sequence one or more peptide bonds have been modified, such as, for example, carba, retro, inverso, retro-inverso, reduced and methylenoxy bonds,

(g) any polypeptide at least one antigen of which is recognized by an antibody directed against a reference polypeptide,

the percentage identity characterizing the homology of two peptide fragments compared is, according to the present invention, at least 50% and preferably at least 70%.

In view of the fact that a virus possessing reverse transcriptase enzymatic activity may be genetically characterized equally well in RNA and in DNA form, both the viral DNA and RNA will be referred to for characterizing the sequences relating to a virus possessing such reverse transcriptase activity, termed MSRV-1 according to the present description.

The expressions of order used in the present description and the claims, such as "first nucleotide sequence", are not adopted so as to express a particular order, but so as to define the invention more clearly.

Detection of a substance or agent is understood below to mean both an identification and a quantification, or a separation or isolation, of the said substance or said agent.

A better understanding of the invention will be gained on reading the detailed description which follows, prepared with reference to the attached figures:

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 shows general consensus sequences of nucleic acids of the MSRV-1B clones amplified by the PCR technique in the "pol" region defined by Shih (12), from viral DNA originating from the LM7PC and PLI-2 lines, and identified under the references SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO: 6, and the common consensus with amplification primers bearing the reference SEQ ID NO:7;

FIG. 2 gives the definition of a functional reading frame for each MSRV-1B/"PCR pol" type family, the said families A to D being defined, respectively, by the nucleotide sequences SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6 described in FIG. 1;

FIG. 3 gives an example of consensus of the MSRV-2B sequences, identified by SEQ ID NO:11;

FIG. 4 is a representation of the reverse transcriptase (RT) activity in dpm (disintegrations per minute) in the sucrose fractions taken from a purification gradient of the virions produced by the B lymphocytes in culture from a patient suffering from MS;

FIG. 5 gives, under the same experimental conditions as in FIG. 4, the assay of the reverse transcriptase activity in the culture of a B lymphocyte line obtained from a control free from MS;

FIG. 6 shows the nucleotide sequence of the clone PSJ17 (SEQ ID NO:9);

FIG. 7 shows the nucleotide sequence SEQ ID NO:8 of the clone designated M003-P004;

FIG. 8 shows the nucleotide sequence SEQ ID NO:2 of the clone F11-1; the portion located between the two arrows in the region of the primer corresponds to a variability imposed by the choice of primer which was used for the cloning of F11-1; in this same figure, the translation into amino acids is shown;

FIG. 9, split into two successive FIGS. 9a and 9b, shows the nucleotide sequence SEQ ID NO:1, and a possible functional reading frame of SEQ ID NO:1 in terms of amino acids; on this sequence, the consensus sequences of the pol gene are underlined;

FIGS. 10 and 11 give the results of a PCR, in the form of a photograph under ultraviolet light of an ethidium bromide-impregnated agarose gel, of the amplification products obtained from the primers identified by SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18 and SEQ ID NO:19;

FIG. 12 gives a representation in matrix form of the homology between SEQ ID NO:1 of MSRV-1 and that of an endogenous retrovirus designated HSERV9; this homology of at least 65% is demonstrated by a continuous line, the absence of a line meaning a homology of less than 65%;

FIG. 13 shows the nucleotide sequence SEQ ID NO:46 of the clone FBd3;

FIG. 14 shows the sequence homology between the clone FBd3 and the HSERV-9 retrovirus;

FIG. 15 shows the nucleotide sequence SEQ ID NO:51 of the clone t pol;

FIGS. 16 and 17 show, respectively, the nucleotide sequences SEQ ID NO:52 and SEQ ID NO:53 of the clones JLBc1 and JLBc2, respectively;

FIG. 18 shows the sequence homology between the clone JLBc1 and the clone FBd3;

and FIG. 19 the sequence homology between the clone JLBc2 and the clone FBd3;

FIG. 20 shows the sequence homology between the clones JLBc1 and JLBc2;

FIGS. 21 and 22 show the sequence homology between the HSERV-9 retrovirus and the clones JLBc1 and JLBc2, respectively;

FIG. 23 shows the nucleotide sequence SEQ ID NO:56 of the clone GM3;

FIG. 24 shows the sequence homology between the HSERV-9 retrovirus and the clone GM3;

FIG. 25 shows the localization of the different clones studied, relative to the genome of the known retrovirus ERV9;

FIG. 26 shows the position of the clones F11-1, M003-P004, MSRV-1B and PSJ17 in the region hereinafter designated MSRV-1 pol*;

FIG. 27, split into three successive FIGS. 27a, 27b and 27c, shows a possible reading frame covering the whole of the pol gene;

FIG. 28 shows, according to SEQ ID NO:40, the nucleotide sequence coding for the peptide fragment POL2B, having the amino acid sequence identified by SEQ ID NO:39;

FIG. 29 shows the OD values (ELISA tests) at 492 nm obtained for 29 sera of MS patients and 32 sera of healthy controls tested with an anti-IgG antibody;

FIG. 30 shows the OD values (ELISA tests) at 492 nm obtained for 36 sera of MS patients and 42 sera of healthy controls tested with an anti-IgM antibody;

FIGS. 31 to 33 show the results obtained (relative intensity of the spots) for 43 overlapping octapeptides covering the amino acid sequence 61-110, according to the Spotscan technique, respectively with a pool of MS sera, with a pool of control sera and with the pool of MS sera after deduction of a background corresponding to the maximum signal detected on at least one octapeptide with the control serum (intensity=1), on the understanding that these sera were diluted to 1/50. The bar at the far right-hand end represents a graphic scale standard unrelated to the serological test;

FIG. 34 shows the SEQ ID NO:41 and SEQ ID NO:42 of two polypeptides comprising immunodominant [lacuna], while SEQ ID NO:43 and 44 represent immunoreactive polypeptides specific to MS;

FIG. 35 shows the nucleotide sequence SEQ ID NO:59 of the clone LB19 and three potential reading frames of SEQ ID NO:59 in terms of amino acids;

FIG. 36 shows the nucleotide sequence SEQ ID NO:88 (GAG*) and a potential reading frame of SEQ ID NO:88 in terms of amino acids;

FIG. 37 shows the sequence homology between the clone FBd13 and the HSERV-9 retrovirus; according to this representation, the continuous line means a percentage homology greater than or equal to 70% and the absence of a line means a smaller percentage homology;

FIG. 38 shows the nucleotide sequence SEQ ID NO:61 of the clone FP6 and three potential reading frames of SEQ ID NO:61 in terms of amino acids;

FIG. 39 shows the nucleotide sequence SEQ ID NO:89 of the clone G+E+A and three potential reading frames of SEQ ID NO:89 in terms of amino acids;

FIG. 40 shows a reading frame found in the region E and coding for an MSRV-1 retroviral protease identified by SEQ ID NO:90;

FIG. 41 shows the response of each serum of patients suffering from MS, indicated by the symbol (+), and of healthy patients, symbolised by (-), tested with an anti-IgG antibody, expressed as net optical density at 492 nm;

FIG. 42 shows the response of each serum of patients suffering from MS, indicated by the symbols (+) and (QS), and of healthy patients (-), tested with an anti-IgM antibody, expressed as net optical density at 492 nm.

PATENT EXAMPLES This data is not available for free
PATENT PHOTOCOPY Available on request

Want more information ?
Interested in the hidden information ?
Click here and do your request.


back